Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Decitabine in R/R AML
NCT02996474Phase 2Completed
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Dec 2016
- Primary completion
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in acute myeloid leukemia (AML), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Feasibility of a Novel Combination of Pembrolizumab and Decitabine at 24 weeks. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02996474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996474.